Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingyi No. 4
- Development stage
- Preclinical
- Lead developer
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Qingyi No. 4 is a Traditional Chinese Medicine (TCM) granule developed for the treatment of Epidemic hemorrhagic fever (Hemorrhagic fever with renal syndrome). It is intended for use in an integrated approach combining traditional Chinese and Western medicine. As a TCM, it is composed of multiple active compounds, typically derived from various herbs. While specific mechanisms for Qingyi No. 4 in Epidemic hemorrhagic fever are not detailed, related Qingyi Decoction formulations have demonstrated anti-inflammatory effects and regulation of apoptosis in other conditions, suggesting a broad-acting mechanism.
- Other names
- Qingyi No. 4 granule
Beyond the preview
Go deeper on Qingyi No. 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingyi No. 4.